Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

In some ways, pharma connecting directly with patients isn’t novel at all: pharma companies in the United States have been ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

This kind of voluntary information that customers share directly with advertisers is known as zero-party data – and it has ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The idea of direct-to-patient channels in pharma conjures up services like Lilly Direct and PfizerForAll. But ...

MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, bolstering its ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, ...